Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

New Thinking, New Strategies in Advanced Urothelial Carcinoma

Access Activity

Overview / Abstract:


Bladder cancer is the sixth most common malignancy among adults in the United States. Approximately 80,470 new cases are diagnosed annually and 17,670 people die of the disease. More than 90% of patients with bladder cancer have the urothelial carcinoma subtype, which has a high rate of recurrence whether it is low or high grade. Approximately half of all bladder cancers are diagnosed in situ, for which the 5-year relative survival rate is 95%. For tumors diagnosed as a localized, regional, or distant stage, the 5-year survival rate declines to 69%, 35%, and 5%, respectively.


Military, academic, and private practice urologists and other health care professionals involved in the treatment of patients with urothelial carcinoma.


1.) Evaluate patient- and tumor-related factors that can inform personalized care plans for patients with urothelial carcinoma
2.) Differentiate the mechanism of action of novel therapies for locally advanced/metastatic urothelial carcinoma
3.) Assess emerging clinical evidence on novel treatment approaches for patients with locally advanced/metastatic urothelial carcinoma, including those ineligible for cisplatin-based chemotherapy


Jan 28, 2021


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Arjun V. Balar, MD (Chairperson)
Assistant Professor of Medicine
NYU Langone Health

Activity Specialities / Related Topics

Urology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Merck.

Keywords / Search Terms

i3 Health i3 Health, urothelial carcinoma, urology, urologic oncology, CME, CNE, online CME, online CNE, free CME, free CNE Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.